September 13, 2019 Licensing, IP, and Legal PR/Corporate Product Launch

Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis

Basel, 13 September 2019 Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment... Read more

September 13, 2019 PR/Corporate

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer

Basel, 13 September 2019 Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, including the... Read more

September 12, 2019 Bio/Pharma/CRO

Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

Basel, 12 September 2019 Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for satralizumab monotherapy versus placebo... Read more

September 12, 2019 Bio/Pharma/CRO

Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

Basel, 12 September 2019 Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data... Read more

September 10, 2019 Licensing, IP, and Legal PR/Corporate Product Launch

Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS

Basel, 10 September 2019 Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future... Read more

September 6, 2019 Uncategorized

European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer

Basel, 06 September 2019 European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung... Read more

September 6, 2019 Clinical Research/Diagn. Product Launch

European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

Basel, 06 September 2019 European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus... Read more

September 5, 2019 Clinical Research/Diagn.

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy CARLSBAD, Calif., Sept. 5, 2019 /PRNewswire/ — Tumor mutational burden (TMB) has recently emerged as a potential biomarker to help guide ICI (immune checkpoint inhibitor) therapy. A new study published in The Journal of Pathology further establishes TMB’s... Read more

September 4, 2019 PR/Corporate

Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS

Basel, 04 September 2019 Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain levels as a... Read more

September 3, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 03 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more